

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Laser Therapy for Diabetic Peripheral Neuropathy: Protocol of a Systematic Review and Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059476
Article Type:	Protocol
Date Submitted by the Author:	25-Nov-2021
Complete List of Authors:	Wang, Jiayou; Shanghai University of Traditional Chinese Medicine Zouqin, Huang; Shanghai Pudong Hospital of Traditional Chinese Medicine Deng, Haiping; Shanghai University of Traditional Chinese Medicine Zhao, Ling; Shanghai University of Traditional Chinese Medicine Hongyong, Deng; Shanghai University of Traditional Chinese Medicine Shen, Xueyong; Meridian Cheng, Ke; Meridian
Keywords:	Laser therapy < DERMATOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, Medical physics < RADIOTHERAPY

SCHOLARONE™
Manuscripts

Laser Therapy for Diabetic Peripheral Neuropathy: Protocol of a Systematic Review and Meta-analysis

Mr. Wang Jiayou, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine. 18702590670@163.com

Dr. Huang Zouqin, Shanghai Pudong Hospital of Traditional Chinese Medicine, Shanghai, China. hzqmusic@yeah.net

Dr. Deng Haiping, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine. hpdeng307@126.com

Dr. Zhao Ling, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine. zhao3helen@sina.com

Dr. Deng Hongyong, Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine. depew@126.com

Dr. Shen Xueyong, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian. snowysh@hotmail.com

Dr. Cheng Ke, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian. Cheng_ker@hotmail.com

Corresponding author: Cheng Ke, Shen Xueyong

Wang Jiayou and Huang Zouqin contribute equally on this article.

ABSTRACT

Introduction: Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes, and strongly impact the quality of life and working ability of patients. Evidence indicated that laser therapy might be effective for neuropathy, however, the effect of laser therapy for DPN is not clear. The objective of this systematic review and meta-analysis is to determine the effectiveness and safety of laser therapy for DPN, in comparison with sham laser therapy, no treatment, or other active treatment, or as an additional treatment compared with another treatment alone.

Methods and analysis: We will search PubMed (MEDLINE), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science, as well as four Chinese language databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP Chinese Science and Technology Journal Database and SinoMed. Randomized controlled trials will be included. Two reviewers will independently extract data using a structured data extraction method and assess the risk of bias in the included studies. We will conduct meta-analysis with RevMan 5.3 and evaluate quality of the evidence with GRADE approach.

Ethics and dissemination: This study doesn't require ethics approval. Our findings will

1
2
3 be disseminated in the peer-reviewed publications.

4
5 **Systematic review registration:** submitted in PROSPERO ID: CRD42021276056

6 7 8 **Strengths and limitations of this study**

- 9
10 ● We will update the search to date to include more recent studies and will expand our
11 search scope to Chinese language databases.
- 12
13 ● We will evaluate more outcomes including global symptom improvement and other
14 patient-reported outcomes including pain, function impairment and quality of life, as
15 well as adverse events.⁷
- 16
17 ● We only search English and Chinese databases, but not other language databases,
18 which may increase reporting bias.

19 20 **INTRODUCTION**

21
22
23 Diabetic peripheral neuropathy (DPN), one of the most common complications of
24 diabetes, strongly impact the quality of patients' life and capacity for work. It leads to foot
25 ulcer in 50% diabetes, and even cause lower limb amputation. People with type 2
26 diabetes suffered more risks of DPN than type 1.^[1] DPN is recognized by the damage of
27 peripheral nerve, which commonly occur in lower limbs, and hands were occasionally
28 affected. However, up to 50% of patients never experience symptoms, thus the diagnosis
29 only can be made in accidental examination or until the foot ulcer appear. For patients
30 who have already experienced symptoms, numbness, dryness, burning pain, needle-like
31 pain and some other abnormal sensations are most frequently mentioned. ^[2]

32
33
34
35
36 The biggest risk factors of DPN are chronic hyperglycemia exposure and diabetes
37 duration. Whereas some other factors, including hypertension, hyperlipidaemia, smoking,
38 age at onset of diabetes, type of diabetes and genetic factors, may also play a role at
39 varying degrees. ^[3,4]

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Enhanced glucose control is the only way that has been proved to be effective for
preventing the development of diabetic neuropathy. It could reduce nerve conduction and
vibration threshold abnormalities in type 1 diabetes, while in type 2 diabetes, the
effectiveness was not statistically significant. In addition, enhanced glucose control can
increase the risk of severe hypoglycemic episodes.^[5] Some symptomatic therapies, such
as the tricyclic antidepressants; selective serotonin-reuptake inhibitors; antiepileptics;
zonisamide and non-steroidal anti-inflammatory drugs (NSADs), has been proved to be
effective for painful symptom. Nevertheless, these drugs are accompanied with varies of
adverse events, including dry mouth, sedation, dizziness, confusion, orthostatic
hypotension, headache, nausea, constipation, diarrhea, etc.^[6]

Non-pharmacological therapy, such as laser therapy, especially low level laser, has also
been used to treat DPN due to its function in alleviating pain^[7] and improving lower limbs

1
2
3 sensation^[8,9]. The mechanism of laser action is not completely clearly. It may inhibit
4 apoptosis and increasing neurogenesis so that the damage of nervous system can be
5 recovered. The effect of laser therapy is closely related to the type of laser, irradiation
6 mode, power density and the properties of irradiated tissue.^[10]
7
8

9
10 While two systematic reviews have evaluated the effects of laser therapy for DPN,^[11, 12]
11 they both included only a small number of studies, and one of them only provided
12 qualitative description of the included studies. With some new and larger-
13 sample size RCTs^[13-16] published, it is important to conduct an update of the systematic
14 review and meta-analysis of laser therapy for DPN.
15
16

17 18 **OBJECTIVE**

19
20
21 The objective of this review is to determine the benefit and potential harm of laser
22 therapy, in comparison to sham laser therapy, no treatment, or other active treatment, or
23 as an additional treatment compared with another treatment alone in patients with DPN.
24
25

26 27 **METHOD AND ANALYSIS**

28 29 ● **Eligibility criteria for included studies**

30 31 **Types of studies**

32
33 We will include randomized controlled trials assessing the benefits and harms of laser
34 therapy for DPN. Trials with randomization of interventions taking place within individuals
35 to different body parts (e.g., to the two legs) will also be included.
36
37
38

39 40 **Types of population**

41
42 We will include participants of any age and sex, with either form of diabetes, that were
43 diagnosed to be DPN.
44
45

46 47 **Types of intervention**

48
49 Laser therapies for DPN mainly refers to using non-invasively low-level laser or
50 photobiomodulation in the treatment of DPN. The types of laser may include ultraviolet
51 light such as nitrogen molecular laser (337.1nm); violet laser such as helium-cadmium
52 laser (441.6nm); red laser such as argon ion laser (514.5nm) and He-Ne laser (632.8), as
53 well as infrared laser such as semiconductor laser (805nm) and CO₂ laser (10.6µm).^[17]
54
55
56

57 58 **Types of outcome measures**

Main outcome

The main outcome will be global symptom improvement measured by a validated instrument such as Michigan neuropathy screening instrument (MNSI), Michigan diabetic neuropathy score (MDNS), Toronto clinical scoring system (TCSS) or visual analogue scale (VAS).

Additional outcomes

1. Change in or absolute values of pain evaluated by the visual analogue scale (VAS), numeric rating scale (NRS) or verbal description scale (VDS), etc;
2. Change in or absolute values of functional impairment and disability by NIS (Neuropathy Impairment Score) or NDS (Neuropathy defects Score);
2. Change in or absolute values of impairment of sensation in quantitative sensory testing (e.g., vibration perception threshold and thermal threshold);
3. Change in or absolute values of quality of life by SF-36 or NeurQol, etc;
4. Change in or absolute values of nerve conduction function measured by motor or sensory nerve conduction velocity (NCV), sensory nerve action potential (SNAP) or compound muscle action potential (CMAP);
5. Number of participants experiencing adverse events;
6. Serious adverse events.

The time point of follow-up will be at equal or less than 3 months (closest to 2 months) after randomization for short term and at more than 3 months (closest to 6 months) after randomization for long term.

● Search methods for identification of studies

We will search, with no time and language restrictions, the following databases for relevant literature: PubMed (MEDLINE), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science, as well as Chinese language databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP Chinese Science and Technology Journal Database (VIP) and SinoMed. Two trial registries including Clinical Trials.gov and the World Health Organization International Clinical Trials Registry Platform (<https://trialsearch.who.int/>) will be also searched. The electronic database search will be supplemented by a manual search of the reference lists of included articles. The search strategy is shown in Table. 1.

● Data collection and analysis

Study selection

At least one author will screen the title and abstract of all records identified by searching. We will obtain the full text of potentially relevant reports and two authors will independently review the full text to assess its eligibility. We will resolve disagreements by discussion.

Data extraction and management

Two review authors (JYW and ZQH) independently will extract data concerning details of study population, intervention, and outcomes using a structured data extraction form following the section 7.7 of Cochrane Handbook.^[18] We will consult the other review author (KC) if there is any conflict.

If the publication did not report outcome data or the data was reported ambiguously, we will request the corresponding authors of the study to provide additional information or clarification by email.

Assessment of treatment adequacy

Two experts, who have a clinical or research experience of more than 5 years in laser therapy or in DPN treatment, and who have previously worked on RCTs or systematic reviews, will independently assess the adequacy of the laser therapy and the control therapy in the trials. Five aspects of the laser treatment will be assessed for adequacy: 1) selection of laser (including wavelength, power density and energy density) 2) choice of irradiation location; 3) total number of sessions; 4) treatment duration; 5) treatment frequency. The validity of the sham intervention will also be assessed to using an open-ended question. The experts will be provided with only the part of each publication that describes the laser and control procedures, so that their assessments cannot be influenced by the results of the trials. Discrepancies between the two experts will achieve consensus by discussion.

Assessment of risk of bias

Two review authors (JYW and ZQH) independently will assess the risk of bias in the studies that were included in this review according to the criteria described in the section 8.2.3 of Cochrane Handbook for Systematic Reviews of Interventions.^[19] We will resolve conflicts by consulting the other review author (KC).

The items involve the following domains: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias.

Measures of treatment effect

1
2
3 Mean difference or standards mean difference with 95% CI will be used for continues
4 outcome and odds ratios (OR) or relative ratios (RR) with 95% CI will be used for
5 dichotomous data.
6
7

8 **Unit of analysis issues**

9

10 We will also include data from trials with different interventions being applied to different
11 body parts, if the information is available. The analysis will be account for the pairing of
12 parts within individuals in the same way that pairing of intervention periods in the
13 crossover trial.^[20] Continuous data from this kind of trial will be analyzed using one of the
14 two approaches: use the results from paired analyses if reported in the original article;
15 treat the study as a parallel trial and pool the interventional parts and compare these to
16 the pooled control parts. Dichotomous outcomes for this kind of trial require more
17 complicated analysis methods and we will consult with a statistician. ^[21]
18
19
20
21

22 **Dealing with missing data**

23

24 For the missing data, we will contact the original author. If it's failed to gather the missing
25 data, we will discuss the potential impact of the dropout for the conclusion of the review.
26
27

28 **Assessment of heterogeneity**

29

30 We will use I^2 statistic to assess Statistical heterogeneity. If the I^2 value greater than
31 50%, we will conduct subgroups to explore the sources of heterogeneity.
32
33

34 **Reporting bias**

35

36 We will make a funnel plot to assess publication bias if the number of studies is more
37 than 10.
38
39
40

41 **Data synthesis and sensitivity analysis**

42

43 Data of studies that are sufficiently similar in terms of their comparisons and
44 outcome measurements will be pooled. The data will be pooled by using random-effects
45 model when studies are heterogeneous, and on the contrary, by using fixed-effect model
46 when they are homogeneous. We will report the data separately if the study can't be
47 combined. We will use mean difference (MD) for single trial comparisons and for RCTs
48 that used same instrument to measure the same outcome. For the RCTs that assessed
49 same outcome by various instruments, we will use standard mean difference
50 (SMD). Analyses will be performed by intention to treat, where possible.
51
52
53

54 We will perform sensitivity analysis excluding the trials with high risk of bias when data
55 are adequate.
56
57

58 **Subgroup analysis**

59
60

1
2
3 If we find sufficient number of RCTs, we will perform subgroup analyses according to:
4
5

6 1. type of diabetes (type 1 or type 2 diabetes mellitus)
7

8 2. type of laser (red, infrared, or other)
9

10 3. dosage of laser treatment: including power density, energy density, as well as duration
11 and frequency of the treatment according to the assessment results of treatment
12 adequacy by the experts.
13
14

15 **Confidence in cumulative evidence** 16

17
18 We will use GRADE system to assess the confidence of our evidence considering five
19 criteria: study limitations, consistency of effect, imprecision, indirectness, and publication
20 bias. We will conduct the assessment in terms of section 14.2 of Cochrane Handbook
21 [22] by GRADEpro software.
22
23

24 **Patient and Public Involvement** 25

26
27 This is a study for systematic review which will not involve patients and public.
28
29

30 **DISCUSSION** 31

32
33 Up to now, evidences for laser therapy treating diabetic peripheral neuropathy are
34 deficient. A 2017 systematic review researched the efficacy of infrared laser for
35 DPN.^[12] The other systematic review published more recently in 2019 studied low-level
36 laser therapy (LLLT) for painful diabetic neuropathy.^[11] The two reviews included only
37 six studies, respectively. Three studies in the 2019 review ^[11] were non-RCTs, thus the
38 2019 review only narratively described the results of the individual
39 study without conducting any meta-analysis or assessing risk of bias of the included
40 studies. In addition, the conclusions of the two reviews were inconsistent.
41
42
43
44

45 Compared to the two previous reviews, we will update the search to date to include more
46 recent studies and will expand our search scope to Chinese language databases to
47 collect more evidences. Additionally, we will include more types of lasers, not
48 focusing only on infrared laser as in the 2017 review, since lasers other than infrared
49 laser are also commonly used in clinic for DPN. In terms of the outcomes, the
50 2017 review ^[12] investigated plantar tactile sensitivity and pain; the 2019 review
51 ^[12] focused on pain and nerve conduction velocity. While we are more concerned
52 about global symptom, because global symptom outcome is more patient-centered and
53 more comprehensive, including various forms of pain and various abnormal sensations in
54 DPN patients. Besides global symptom, we will also consider additional outcomes such
55 as sensation impairment, nerve conduction function, quality of life and adverse events.
56 Compared with the 2017 review ^[12] which performed subgroup analysis according to the
57
58
59
60

1
2
3 type of comparison and length of follow-up, we will carry out subgroup analysis
4 considering more on the differences in the populations and intervention
5 characteristics (e.g., type of diabetes, type of laser and dosage of therapy) according to
6 the suggestion in Cochrane Handbook.^[23]
7
8

9
10 The limitation of our review may be that we only search English and Chinese databases,
11 but not other language databases, which may increase reporting bias.
12

13
14 In conclusion, our review will integrate more and newer clinical trials and will provide
15 more recent and rigorous evidence for the effectiveness and safety of laser therapy in
16 treating DPN.
17

18 **List of abbreviations**

19
20
21 DPN; diabetic peripheral neuropathy; VAS: visual analogue scale; MNSI: Michigan
22 neuropathy screening instrument; MDNS: Michigan diabetic neuropathy score; TCSS:
23 Toronto clinical scoring system; NIS: Neuropathy Impairment Score; NDS; Neuropathy
24 defects Score; NCV: never conduction velocity; CMAP: compound muscle action
25 potential. SNAP: sensory nerve action potential.
26
27
28

29 **DECLARE**

30 **Ethics and dissemination**

31
32 This study doesn't require ethics approval. Our findings will be disseminated in the peer-
33 reviewed publications.
34
35
36

37 **Contributors**

38
39 KC and XS conceived and designed the topic; KC, JYW, and ZQH contributed to writing
40 the protocol; all of the authors commented on the drafts of the protocol.
41
42
43

44 **Funding**

45
46 This study is supported by National Key R&D Program of China (Grand No.
47 2019YFC1709803) and National Natural Science Foundation of China (Grand No.
48 81873183).
49
50

51 **Availability of data and materials**

52
53 The datasets generated and/or analyzed during the current study will be available from
54 the corresponding author according to the institution guideline on materials and data
55 transfer agreements.
56
57
58

59 **Competing interests**

The authors declare that they have no competing interests

REFERENCE

1. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep*. 2019 Aug 27;19(10):86.
2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care*. 2005 Apr;28(4):956-62.
3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep*. 2019 Aug 27;19(10):86.
4. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. *Int J Clin Pract*. 2006 Nov;60(11):1471-83.
5. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev*. 2012 Jun 13;6(6):CD007543.
6. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. *Am J Health Syst Pharm*. 2004 Jan 15;61(2):160-73; quiz 175-6.
7. Nawfar SA, Yacob NB. Effects of monochromatic infrared energy therapy on diabetic feet with peripheral sensory neuropathy: a randomised controlled trial. *Singapore Med J*. 2011 Sep;52(9):669-72.
8. Harkless LB, DeLellis S, Carnegie DH, Burke TJ. Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy--MIRE. *J Diabetes Complications*. 2006 Mar-Apr;20(2):81-7.
9. DeLellis SL, Carnegie DH, Burke TJ. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. *J Am Podiatr Med Assoc*. 2005 Mar-Apr;95(2):143-7.
10. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. *Ann Biomed Eng*. 2012 Feb;40(2):516-33.
11. M A, Ummer V S, Maiya AG, Hande M. Low level laser therapy for the patients with painful diabetic peripheral neuropathy - A systematic review. *Diabetes Metab Syndr*. 2019 Jul-Aug;13(4):2667-2670. doi: 10.1016/j.dsx.2019.07.035. Epub 2019 Jul 13.
12. Robinson CC, Klahr PDS, Stein C, Falavigna M, Sbruzzi G, Plentz RDM. Effects of monochromatic infrared phototherapy in patients with diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Braz J Phys Ther*. 2017 Jul-Aug;21(4):233-243.
13. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, Kumar V, De Taboada L, Dey AB. Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial. *BMC Geriatr*. 2019 Aug 12;19(1):218. doi: 10.1186/s12877-019-1237-5.
14. da Silva Leal MV, Lima MO, Nicolau RA, de Carvallho TMT, Abreu JAC, Pessoa DR, Arisawa EALS. Effect of Modified Laser Transcutaneous Irradiation on Pain and

- 1
2
3 Quality of Life in Patients with Diabetic Neuropathy. *Photobiomodul Photomed Laser Surg.* 2020 Mar;38(3):138-144. doi: 10.1089/photob.2019.4714.
- 4
5
6 15. Shanb AA, Youssef EF, Al Baker WI, Al-Khamis FA, Hassan A, Jatoi NA. The
7 Efficacy of Adding Electromagnetic Therapy or Laser Therapy to Medications in
8 Patients With Diabetic Peripheral Neuropathy. *J Lasers Med Sci.* 2020
9 Winter;11(1):20-28. doi: 10.15171/jlms.2020.05. Epub 2020 Jan 18.
- 10
11 16. Meyer-Hamme G, Friedemann T, Greten J, Gerloff C, Schroeder S.
12 Electrophysiologically verified effects of acupuncture on diabetic peripheral
13 neuropathy in type 2 diabetes: The randomized, partially double-blinded, controlled
14 ACUDIN trial. *J Diabetes.* 2021 Jun;13(6):469-481. doi: 10.1111/1753-0407.13130.
15 Epub 2020 Dec 2.
- 16
17 17. Arjmand B, Khodadost M, Jahani Sherafat S, Rezaei Tavirani M, Ahmadi N,
18 Hamzeloo Moghadam M, Okhovatian F, Rezaei Tavirani S, Rostami-Nejad M. Low-
19 Level Laser Therapy: Potential and Complications. *J Lasers Med Sci.* 2021 Aug
20 4;12:e42. doi: 10.34172/jlms.2021.42.
- 21
22 18. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7:
23 Considering bias and conflicts of interest among the included studies. In: Higgins
24 JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
25 *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated*
26 *February 2021).* Cochrane, 2021. Available
27 from www.training.cochrane.org/handbook.
- 28
29 19. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk
30 of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
31 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
32 *Interventions version 6.2 (updated February 2021).* Cochrane, 2021. Available from
33 www.training.cochrane.org/handbook.
- 34
35 20. Higgins JPT, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized
36 trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
37 VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version*
38 *6.2 (updated February 2021).* Cochrane, 2021. Cochrane, 2021. Available from
39 www.training.cochrane.org/handbook.
- 40
41 21. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-
42 analyses involving cross-over trials: methodological issues. *Int J Epidemiol.* 2002
43 Feb;31(1):140-9.
- 44
45 22. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH.
46 Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the
47 evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
48 Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
49 *Interventions version 6.2 (updated February 2021).* Cochrane, 2021. Available
50 from www.training.cochrane.org/handbook.
- 51
52 23. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and
53 undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
54 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
55
56
57
58
59
60

Interventions version 6.2 (updated February 2021). Cochrane, 2021. Cochrane, 2021. Available from www.training.cochrane.org/handbook.

Table 1 Search strategy for the MEDLINE (PubMed) database

disease terms

1. "Diabetic Neuropathies"[Mesh]
2. (Diabetic Neuropathy[Title/Abstract] OR Neuropathies, Diabetic[Title/Abstract] OR Neuropathy, Diabetic[Title/Abstract] OR Diabetic Autonomic Neuropathy[Title/Abstract] OR Autonomic Neuropathies, Diabetic[Title/Abstract] OR Autonomic Neuropathy, Diabetic[Title/Abstract] OR Diabetic Autonomic Neuropathies[Title/Abstract] OR Neuropathies, Diabetic Autonomic[Title/Abstract] OR Neuropathy, Diabetic Autonomic[Title/Abstract] OR Diabetic Neuralgia[Title/Abstract] OR Diabetic Neuralgias[Title/Abstract] OR Neuralgias, Diabetic[Title/Abstract] OR Diabetic Neuropathy, Painful[Title/Abstract] OR Diabetic Neuropathies, Painful[Title/Abstract] OR Neuropathies, Painful Diabetic[Title/Abstract] OR Neuropathy, Painful Diabetic[Title/Abstract] OR Painful Diabetic Neuropathies[Title/Abstract] OR Painful Diabetic Neuropathy[Title/Abstract] OR Neuralgia, Diabetic[Title/Abstract] OR Symmetric Diabetic Proximal Motor Neuropathy[Title/Abstract] OR Asymmetric Diabetic Proximal Motor Neuropathy[Title/Abstract] OR Diabetic Asymmetric Polyneuropathy[Title/Abstract] OR Asymmetric Polyneuropathies, Diabetic[Title/Abstract] OR Asymmetric Polyneuropathy, Diabetic[Title/Abstract] OR Diabetic Asymmetric Polyneuropathies[Title/Abstract] OR Polyneuropathies, Diabetic Asymmetric[Title/Abstract] OR Polyneuropathy, Diabetic Asymmetric[Title/Abstract] OR Diabetic Mononeuropathy[Title/Abstract] OR Diabetic Mononeuropathies[Title/Abstract] OR Mononeuropathies, Diabetic[Title/Abstract] OR Mononeuropathy, Diabetic[Title/Abstract] OR Diabetic Mononeuropathy Simplex[Title/Abstract] OR Diabetic Mononeuropathy Simplicis[Title/Abstract] OR Mononeuropathy Simplex, Diabetic[Title/Abstract] OR Mononeuropathy Simplicis, Diabetic[Title/Abstract] OR Simplex, Diabetic Mononeuropathy[Title/Abstract] OR Simplicis, Diabetic Mononeuropathy[Title/Abstract] OR Diabetic Amyotrophy[Title/Abstract] OR

Amyotrophies, Diabetic[Title/Abstract] OR Amyotrophy, Diabetic[Title/Abstract]
OR Diabetic Amyotrophies[Title/Abstract] OR Diabetic
Polyneuropathy[Title/Abstract] OR Diabetic Polyneuropathies[Title/Abstract]
OR Polyneuropathies, Diabetic[Title/Abstract] OR Polyneuropathy,
Diabetic[Title/Abstract])

3. 1 OR 2

intervention terms

4. "laser therapy"[MeSH Terms]

5. (Infrared Ray[Title/Abstract] OR Ray, Infrared[Title/Abstract] OR Rays,
Infrared[Title/Abstract] OR Heat Waves[Title/Abstract] OR Therapy, Near
Infrared[Title/Abstract] OR Phototherapies[Title/Abstract] OR Therapy,
Photoradiation[Title/Abstract] OR Photoradiation Therapies[Title/Abstract] OR
Therapies, Photoradiation[Title/Abstract] OR Light Therapy[Title/Abstract] OR
Light Therapies[Title/Abstract] OR Therapies, Light[Title/Abstract] OR Therapy,
Light[Title/Abstract] OR Photoradiation Therapy[Title/Abstract] OR Light
Therapies[Title/Abstract] OR Therapies, Light[Title/Abstract] OR Light
Irradiation[Title/Abstract] OR Irradiation, Light[Title/Abstract] OR Light
Phototherapy[Title/Abstract] OR Phototherapy, Ligth[Title/Abstract] OR Light
Biostimulation[Title/Abstract] OR Monochromatic Near Infrared
Therapy[Title/Abstract] OR Therapy, Monochromatic Near
Infrared[Title/Abstract] OR MIRE[Title/Abstract] OR Anodyne
Theraphy[Title/Abstract] OR Therapy, Anodyne[Title/Abstract] OR
PILT[Title/Abstract] OR Pulsed Infrared Light Therapy[Title/Abstract] OR Light
Emitting[Title/Abstract] OR Photo Energy[Title/Abstract] OR Light Emitting
Diodes[Title/Abstract] OR Laser Therapies[Title/Abstract] OR Therapies,
Laser[Title/Abstract] OR Therapy, Laser[Title/Abstract]) OR
Laser[Title/Abstract]

6. 4 OR 5

7. 3 AND 6

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	8
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not amendments
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	8
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	8
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	3
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	11

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	5
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	4
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	5
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	3
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	5
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	6
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	6
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	6
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	6
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	6
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	7

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Low Level Laser Therapy/Photobiomodulation for Diabetic Peripheral Neuropathy: Protocol of a Systematic Review and Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059476.R1
Article Type:	Protocol
Date Submitted by the Author:	06-May-2022
Complete List of Authors:	Wang, Jiayou; Shanghai University of Traditional Chinese Medicine Zouqin, Huang; Shanghai Pudong Hospital of Traditional Chinese Medicine Deng, Haiping; Shanghai University of Traditional Chinese Medicine Zhao, Ling; Shanghai University of Traditional Chinese Medicine Hongyong, Deng; Shanghai University of Traditional Chinese Medicine Liu, Jianping; Beijing University of Chinese Medicine, Centre for Evidence Based Chinese Medicine Shen, Xueyong; Shanghai University of Traditional Chinese Medicine, School of Acupuncture-moxibustion and Tuina; Shanghai Research Center of Acupuncture & Meridian Cheng, Ke; Shanghai University of Traditional Chinese Medicine, School of Acupuncture-moxibustion and Tuina; Shanghai Research Center of Acupuncture & Meridian
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Neurology
Keywords:	Laser therapy < DERMATOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, Neurological pain < NEUROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 Low Level Laser Therapy/Photobiomodulation for Diabetic
5
6 Peripheral Neuropathy: Protocol of a Systematic Review and
7
8
9 Meta-analysis
10
11
12
13

14 Mr. Jia-You Wang, School of Acupuncture-moxibustion and Tuina, Shanghai University
15 of Traditional Chinese Medicine. 18702590670@163.com

16 Dr. Zou-Qin Huang, Shanghai Pudong Hospital of Traditional Chinese Medicine,
17 Shanghai, China. hzqmusic@yeah.net

18 Dr. Hai-Ping Deng, School of Acupuncture-moxibustion and Tuina, Shanghai University
19 of Traditional Chinese Medicine. hpdeng307@126.com

20 Dr. Ling Zhao, School of Acupuncture-moxibustion and Tuina, Shanghai University of
21 Traditional Chinese Medicine. zhao3helen@sina.com

22 Dr. Hong-Yong Deng, Collaborative Innovation Center, Shanghai University of Traditional
23 Chinese Medicine. dephew@126.com

24 Dr. Jian-Ping Liu, Centre for Evidence Based Chinese Medicine, Beijing University of
25 Chinese Medicine, Beijing, 100029, China, liujp@bucm.edu.cn

26 Dr. Xue-Yong Shen, School of Acupuncture-moxibustion and Tuina, Shanghai University
27 of Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian.
28 snowysh@hotmail.com

29 Dr. Ke Cheng, School of Acupuncture-moxibustion and Tuina, Shanghai University of
30 Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian.
31 cheng_ker@hotmail.com

32 Corresponding authors: Ke Cheng, Xue-Yong Shen

33 Jia-You Wang and Zou-Qin Huang contribute equally on this article.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes, and strongly impact the quality of life and working ability of patients. Evidence indicated that Low level laser therapy (LLLT)/photobiomodulation might be effective for neuropathy, however, the effect of LLLT for DPN is not clear. The objective of this systematic review and meta-analysis is to determine the effectiveness and safety of LLLT/photobiomodulation for DPN, in comparison with sham light, no treatment, or other active treatment, or as an additional treatment compared with another treatment alone.

Methods and analysis: We will search eight databases from their inception to July 2022. Randomized controlled trials (RCTs) will be included. Two reviewers will independently extract data using a structured data extraction method and assess the risk of bias in the included studies. Data will be synthesized using standardized mean difference (SMD) or risk ratio (RR) with 95% confidence intervals (CI) for continuous and dichotomous data, respectively. The primary outcome will be change in pain and secondary outcomes will include global symptom improvement, functional impairment and disability, impairment of sensation, quality of life, nerve conduction, as well as adverse events. Sensitivity and subgroup analysis will be employed to explore the influence of possible clinical and methodological characteristics. Publication bias will be assessed using funnel plot. We will conduct meta-analysis with RevMan 5.4 and evaluate quality of the evidence with GRADE approach.

Ethics and dissemination: This study doesn't require ethics approval. Our findings will be disseminated in the peer-reviewed publications.

Systematic review registration: submitted in PROSPERO ID: CRD42021276056

Keywords: low level laser therapy, photobiomodulation, diabetic peripheral neuropathy, pain, systematic review

Strengths and limitations of this study

- We will update the search to date to include more recent studies and will expand our search scope to Chinese language databases.
- We will evaluate more outcomes including pain, global symptom improvement, functional impairment and disability, impairment of sensation, quality of life, nerve conduction, as well as adverse events.
- We only search English and Chinese databases, but not other language databases, which may increase reporting bias.

INTRODUCTION

Diabetic peripheral neuropathy (DPN), one of the most common complications of

1
2
3 diabetes, strongly impact the quality of patients' life and capacity for work. It leads to foot
4 ulcer in 50% diabetes, and even cause lower limb amputation. People with type 2
5 diabetes suffered more risks of DPN than type 1.^[1] DPN is recognized by the damage of
6 peripheral nerve, which commonly occur in lower limbs, and hands were occasionally
7 affected. However, up to 50% of patients never experience symptoms, thus the diagnosis
8 only can be made in accidental examination or until the foot ulcer appear. For patients
9 who have already experienced symptoms, numbness, dryness, burning pain, needle-like
10 pain and some other abnormal sensations are most frequently mentioned. ^[2]

11
12
13
14
15 Significant risk factors for DPN include diabetes duration, age and glycosylated
16 hemoglobin.^[3,4] Some other factors, including hypertension, hyperlipidaemia and obesity
17 may also play a role at varying degrees. ^[5]

18
19
20 Other than improving glycemic control, there is no specific treatment for the underlying
21 nerve damage. Enhanced glucose control can effectively prevent diabetic peripheral
22 neuropathy in type 1 diabetes, whereas the evidence for the effect of glycemic control is
23 not strong in type 2 diabetes.^[6] What's more, enhanced glucose control can increase the
24 risk of severe hypoglycemic episodes.^[6] Some symptomatic therapies, such as
25 pregabalin, duloxetine or gabapentin are recommended as first-line pharmacological
26 treatment for relieving painful symptoms. Tricyclic antidepressants, venlafaxine,
27 carbamazepine, opioids and topical capsaicin are also probably effective in relieving
28 pain.^[7,8] However, these drugs are accompanied with varies of adverse events, including
29 dry mouth, sedation, dizziness, confusion, orthostatic hypotension, headache, nausea,
30 constipation, diarrhea, etc.^[9]

31
32
33
34
35 Non-pharmacological therapy, such as Low level laser therapy (LLLT), has also been
36 used to treat DPN due to its function in alleviating pain^[10] and improving lower limbs
37 sensation^[11,12]. LLLT, also known as photobiomodulation, has been in use from its
38 invention in 1960s. The light used in LLLT is mainly in the red (wavelength of 600-700
39 nm) and near-infrared (NIR, wavelength of 780-1100 nm) region.^[13,14] The red and NIR
40 light is mostly absorbed by the mitochondrial enzyme (i.e., cytochrome-c-oxidase), the
41 key chromophore in the cellular response to LLLT, to increase adenosine triphosphate
42 (ATP) production, modulation of reactive oxygen species (ROS), and the induction of
43 transcription factors. ^[13,14,15] The mid-IR (infrared) including carbon dioxide laser at
44 wavelength of 10.6 μm and broad band IR source in the 10-50 μm are also reported as
45 effective LLLT light, and they are considered to be absorbed by water in some
46 nanostructured form possibly present in biological membranes.^[13] On the tissue level,
47 LLLT has been used to inhibit pain and pathological conditions associated with the
48 nervous system. It exerts potent anti-inflammatory effects in the peripheral nervous
49 system and promotes functional recovery and regeneration of peripheral nerves after
50 injury, also in DPN.^[14,16] The effect of LLLT is also closely related to the type of light,
51 irradiation mode, power density and the properties of irradiated tissue.^[13]

52
53
54
55
56
57
58 Although two systematic reviews have evaluated the effects of
59 LLLT/photobiomodulation for DPN, ^[17, 18] they both included only a small number of
60

1
2
3 studies in English language, and one of them only provided qualitative description of the
4 included studies. With some new and larger-sample size RCTs [19-22] published, it is
5 important to conduct an update of the systematic review and meta-analysis of LLLT for
6 DPN.
7
8
9

10 OBJECTIVE

11
12
13 The objective of this review is to determine the benefit of LLLT/photobiomodulation in
14 relieving pain and global symptoms, improving nerve function as well as quality of life
15 and its potential harm, in comparison to sham light, no treatment, or other active
16 treatment, or as an additional treatment compared with another treatment alone in
17 patients with DPN.
18
19
20

21 METHOD AND ANALYSIS

22 We will use standard methodological procedures following Cochrane Handbook.
23
24

25 ● Eligibility criteria for included studies

26 Types of studies

27 We will include randomized controlled trials assessing the benefits and harms of
28 LLLT/photobiomodulation for DPN. Trials with randomization of interventions taking place
29 within individuals to different body parts (e.g., to the two legs) will also be included.
30
31

32 Types of population

33 We will include participants of any age and sex, with either form of diabetes, that were
34 diagnosed to be DPN.
35
36

37 Types of intervention

38 LLLT/photobiomodulation utilizes non-ionizing forms of light sources, including lasers,
39 LEDs, and broadband light, in the visible and infrared spectrum.^[23] The commonly used
40 lights in DPN may include red (wavelength of 780-1100 nm), NIR (wavelength of 780-
41 1100 nm), mid-IR (e.g., 10.6µm) and broad band IR light in the 10-50 µm.^[13] We will
42 compare true LLLT versus sham LLLT, LLLT versus no specific treatment, LLLT versus
43 other specific treatment, or LLLT plus another treatment (usually conventional treatment)
44 versus another same treatment alone. In order to eliminate confounding effects, we will
45 only include RCTs that used the same co-intervention in each group.
46
47
48
49
50
51
52
53
54
55
56

57 Types of outcome measures

58 Main outcome

1
2
3 The main outcome will be change in pain measured using a validated scale including
4 visual analogue scale (VAS), numeric rating scale (NRS), Likert scale, or verbal
5 description scale (VDS), etc.
6
7

8 **Additional outcomes**

9
10
11 1. Global symptom improvement measured by a validated instrument such as neuropathy
12 symptom score (NSS), Michigan diabetic neuropathy score (MDNS) [24] or Toronto clinical
13 scoring system (TCSS). [25] Where this continuous outcome was not available, the primary
14 outcome will be an improvement of 30% or more in a validated clinical global symptom
15 score. [26]
16
17

18
19 2. Change in functional impairment and disability by neuropathy impairment score (NIS)
20 or neuropathy defects score (NDS) in the lower limbs.
21

22
23 3. Change in impairment of sensation in quantitative sensory testing (e.g., vibration
24 perception threshold, thermal threshold and Semmes-Weinstein Monofilaments (SWM)).
25

26
27 4. Change in quality of life by SF-36 or NeurQol, etc.
28

29
30 5. Change in nerve conduction function measured by motor or sensory nerve conduction
31 velocity (NCV), sensory nerve action potential (SNAP) or compound muscle action
32 potential (CMAP).
33

34
35 6. Number of participants experiencing adverse events.
36

37
38 7. Serious adverse events.

39
40 The time point of follow-up will be at equal or less than 3 months (closest to 2 months)
41 after randomization for short term and at more than 3 months (closest to 6 months) after
42 randomization for long term.
43

44 ● **Search methods for identification of studies**

45
46 We will search, with no time and language restrictions, the following databases for
47 relevant literature: PubMed (MEDLINE), Embase, the Cochrane Central Register of
48 Controlled Trials (CENTRAL) and Web of Science, as well as Chinese language
49 databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP
50 Chinese Science and Technology Journal Database (VIP) and SinoMed. Two trial
51 registries including ClinicalTrials.gov and the World Health Organization International
52 Clinical Trials Registry Platform (<https://trialsearch.who.int/>) will be also searched. The
53 electronic database search will be supplemented by a manual search of the reference
54 lists of included articles. The search strategy is shown in Appendix 1. The last search
55
56
57
58
59
60

1
2
3 date will be the date before the submission of the full review. The studies in Chinese
4 language will be translated by JYW and checked by KC.
5
6

7 ● Data collection and analysis

8 9 **Study selection**

10
11
12 At least one author (JYW or ZQH) will screen the title and abstract of all records identified
13 by searching. We will obtain the full text of potentially relevant reports and two authors
14 (JYW and ZQH) will independently review the full text to assess its eligibility. We will
15 resolve disagreements by discussion. In case of disagreement, a third author (KC) will
16 make the final decision on the study selection.
17
18

19 **Data extraction and management**

20
21
22 Two review authors (JYW and ZQH) independently will extract data concerning details of
23 study population, intervention, and outcomes using a structured data extraction form and
24 enter into Microsoft excel spreadsheet following the section 7.7 of Cochrane
25 Handbook.^[27] We will consult the other review author (KC) if there is any conflict.
26
27

28
29 If the publication did not report outcome data or the data was reported ambiguously, we
30 will request the corresponding authors of the study to provide additional information or
31 clarification by email.
32

33 **Assessment of treatment adequacy**

34
35
36 Two experts, who have a clinical or research experience of more than 5 years in
37 LLLT/photobiomodulation therapy or in DPN treatment, and who have previously worked
38 on RCTs or systematic reviews, will independently assess the adequacy of the light
39 therapy and the control therapy in the trials. Five aspects of the light treatment will be
40 assessed for adequacy: 1) selection of light (including wavelength, power density and
41 energy density) 2) choice of irradiation location; 3) total number of sessions; 4) treatment
42 duration; 5) treatment frequency. The validity of the sham intervention will also be
43 assessed to using an open-ended question. The experts will be provided with only the
44 part of each publication that describes the light and control procedures, so that their
45 assessments cannot be influenced by the results of the trials. Discrepancies between the
46 two experts will achieve consensus by discussion.
47
48
49
50

51 **Assessment of risk of bias**

52
53
54 Two review authors (JYW and ZQH) independently will assess the risk of bias in the
55 studies that were included in this review according to the criteria described in the section
56 8.2.3 of Cochrane Handbook for Systematic Reviews of Interventions.^[28] We will resolve
57 conflicts by consulting the other review author (KC).
58
59
60

1
2
3 The items involve the following domains: sequence generation, allocation concealment,
4 blinding of participants, personnel and outcome assessors, incomplete outcome data,
5 selective outcome reporting, and other sources of bias.
6
7

8 **Measures of treatment effect**

9

10 Mean difference or standardised mean difference with 95% CI will be used for continuous
11 outcome and relative ratios (RR) with 95% CI will be used for dichotomous data. Data
12 of studies that are sufficiently similar in terms of their comparisons and outcome
13 measurements will be pooled. The data will be pooled by using random-effects model
14 when studies are heterogeneous on clinical and methodological characteristics, and on
15 the contrary, by using fixed-effect model when they are homogeneous. We will report the
16 data separately if the study can't be combined. We will use mean difference (MD) for
17 single trial comparisons and for RCTs that used same instrument to measure the same
18 outcome. For the RCTs that assessed same outcome by various instruments, we will use
19 standard mean difference (SMD). Analyses will be performed by intention to treat, where
20 possible.
21
22
23
24
25

26 **Unit of analysis issues**

27

28 We will also include data from trials with different interventions being applied to different
29 body parts, if the information is available. The analysis will account for the pairing of
30 parts within individuals in the same way that pairing of intervention periods in the
31 crossover trial.^[29] Continuous data from this kind of trial will be analyzed using one of the
32 two approaches: use the results from paired analyses if reported in the original article;
33 treat the study as a parallel trial and pool the interventional parts and compare these to
34 the pooled control parts. Dichotomous outcomes for this kind of trial require more
35 complicated analysis methods and we will consult with a statistician.^[30]
36
37
38
39
40

41 **Dealing with missing data**

42

43 For the missing data, we will contact the original author. If it's failed to gather the missing
44 data, we will discuss the potential impact of the dropout for the conclusion of the review.
45

46 **Assessment of heterogeneity**

47

48 We will use I^2 statistic to assess Statistical heterogeneity. If the I^2 value greater than
49 50%, we will conduct subgroups to explore the sources of heterogeneity.
50
51

52 **Reporting bias**

53

54 We will make a funnel plot to assess publication bias if the number of studies is more
55 than 10.
56
57

58 **Sensitivity analysis**

59
60

1
2
3 We will perform sensitivity analysis excluding the trials with high risk of bias when data
4 are adequate. For pooled analyses with continuous data, we will consider analyses
5 based on change scores to be primary analysis, and analyses based on post-treatment
6 scores to be sensitivity analysis.
7
8

9 **Subgroup analysis**

10
11 If we find sufficient number of RCTs, we will perform subgroup analyses according to:

- 12 1. type of diabetes (type 1 or type 2 diabetes mellitus)
- 13
- 14 2. type of light (red, infrared, or other)
- 15
- 16 3. dosage of light treatment: including power density, energy density, as well as duration
- 17 and frequency of the treatment according to the assessment results of treatment
- 18 adequacy by the experts.
- 19
- 20
- 21
- 22
- 23

24 **Confidence in cumulative evidence**

25
26 We will use GRADE system to assess the confidence of our evidence considering five
27 criteria: study limitations, consistency of effect, imprecision, indirectness, and publication
28 bias. We will conduct the assessment in terms of section 14.2 of Cochrane Handbook
29 [31] by GRADEpro software.
30
31
32

33 **DISCUSSION**

34
35 Up to now, evidences for LLLT/photobiomodulation treating diabetic peripheral
36 neuropathy are deficient. A 2017 systematic review focused on the infrared light for
37 DPN.^[18] The other more recent systematic review in 2019 studied LLLT for painful
38 diabetic neuropathy.^[17] Each of the two reviews included only six studies. Among the six
39 studies included the 2019 review, three were non-RCTs, thus the 2019 review only
40 narratively described the results of the individual study without conducting any meta-
41 analysis or assessing risk of bias of the included studies. In addition, the
42 conclusions of the two reviews were inconsistent with each other. That is, the 2017
43 review showed limited evidence of infrared phototherapy resulting in short-term
44 improvement of tactile sensitivity, but not in neuropathic pain relief, whereas the 2019
45 review concluded LLLT is associated with a positive effect in relieving neuropathic pain.
46
47
48
49
50
51

52 Compared to the two previous reviews, we will update the search to date to include more
53 recent studies and will expand our search scope to Chinese language databases to
54 collect more evidences. Additionally, we will include more types of lights, not
55 focusing only on infrared lights as in the 2017 review, since other than infrared light,
56 visible lights are also used in clinic for DPN. In terms of the outcomes, the 2017 review
57 [18] investigated plantar tactile sensitivity and pain; the 2019 review [17] focused on pain
58
59
60

1
2
3 and nerve conduction velocity. In addition to the aforementioned outcomes, we will also
4 be concerned about global symptom improvement, functional impairment and disability,
5 quality of life, as well as adverse events due to the therapy. Compared with the
6 2017 review ^[18] which performed subgroup analysis according to the type of comparison
7 and length of follow-up, we will carry out subgroup analysis considering more on the
8 differences in the populations and intervention characteristics (e.g., type of diabetes, type
9 of light and dosage of therapy) according to the suggestion in Cochrane Handbook.^[32]
10
11
12

13 The limitation of our review may be that we only search English and Chinese databases,
14 but not other language databases, which may increase reporting bias.
15
16

17 In conclusion, our review will be an update of the topic by updating with new trials and
18 sound methodology and thus will provide more rigorous and generalized evidence for the
19 effectiveness and safety of LLLT/photobiomodulation in treating DPN.
20
21

22 **List of abbreviations**

23
24
25 CMAP: compound muscle action potential; DPN; diabetic peripheral neuropathy; LLLT:
26 low level laser therapy; GRADE: grading of recommendations, assessment, development
27 and evaluations; MDNS: Michigan diabetic neuropathy score; MNSI: Michigan
28 neuropathy screening instrument; NCV: nerve conduction velocity; NDS: neuropathy
29 defects score; NeuQoL: quality of life in neurological disorders; NIR: near- infrared; NIS:
30 neuropathy impairment score; NRS: numeric rating scale; RCT: randomized controlled
31 trial; SF-36: 36-item short-form health survey ; SNAP: sensory nerve action potential;
32 TCSS: Toronto clinical scoring system; VAS: visual analogue scale; VDS: Likert scale, or
33 verbal description scale.
34
35
36
37

38 **DECLARE**

39 **Ethics and dissemination**

40
41
42
43 This study doesn't require ethics approval. Our findings will be disseminated in the peer-
44 reviewed publications.
45
46

47 **Contributors**

48
49 JYW: data acquisition and original draft writing; ZQH: clinical guidance, data acquisition
50 and original draft writing; HPD: clinical guidance and draft revision; LZ: clinical guidance
51 and draft revision; HYD: methodology support and draft revision; JPL: methodology
52 support and revision of protocol and manuscript; XYS: topic conception, clinical guidance
53 and revision of manuscript; KC: topic conception, protocol design, original draft writing
54 and revision of manuscript.
55
56
57

58 **Funding**

This work is supported by funding from the National Key R&D Program of China (grand number 2019YFC1709803) and National Natural Science Foundation of China (grand number 81873183). Jian-Ping Liu was partially supported by the NCCIH grant (AT001293 with sub-award No. 020468C). The funder had no role in study design, data collection and analysis, interpretation of result, or writing the manuscript.

Availability of data and materials

The datasets generated and/or analyzed during the current study will be available from the corresponding author according to the institution guideline on materials and data transfer agreements.

Competing interests

Xueyong Shen and Ke Cheng have had a patent issued for a type of laser therapy apparatus simulating the infrared radiation spectrum of traditional Chinese moxibustion (China Invention Patent ZL 200910056991.4; issued December 1, 2010).

REFERENCE

1. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep*. 2019 Aug 27;19(10):86.
2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care*. 2005 Apr;28(4):956-62.
3. Liu X, Xu Y, An M, Zeng Q. The risk factors for diabetic peripheral neuropathy: A meta-analysis. *PLoS One*. 2019 Feb 20;14(2):e0212574.
4. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. *Rev Diabet Stud*. 2015 Spring-Summer;12(1-2):48-62.
5. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. *Int J Clin Pract*. 2006 Nov;60(11):1471-83.
6. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev*. 2012 Jun 13;6(6):CD007543.
7. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology*. 2011 May 17;76(20):1758-65.
8. American Diabetes Association. 11. Microvascular Complications and Foot Care:

- Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021 Jan;44(Suppl 1): S151-S167.
9. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. *Am J Health Syst Pharm*. 2004 Jan 15;61(2):160-73; quiz 175-6.
 10. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, et al. Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial. *BMC geriatrics*. 2019;19(1):218.
 11. Harkless LB, DeLellis S, Carnegie DH, Burke TJ. Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy--MIRE. *J Diabetes Complications*. 2006 Mar-Apr;20(2):81-7.
 12. DeLellis SL, Carnegie DH, Burke TJ. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. *J Am Podiatr Med Assoc*. 2005 Mar-Apr;95(2):143-7.
 13. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. *Ann Biomed Eng*. 2012 Feb;40(2):516-33.
 14. de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. *IEEE J Sel Top Quantum Electron*. 2016 May-Jun;22(3):7000417.
 15. Wang X, Tian F, Soni SS, Gonzalez-Lima F, Liu H. Interplay between up-regulation of cytochrome-c-oxidase and hemoglobin oxygenation induced by near-infrared laser. *Sci Rep*. 2016 Aug 3;6:30540.
 16. da Silva Oliveira VR, Cury DP, Yamashita LB, Esteca MV, Watanabe IS, Bergmann YF, et al. Photobiomodulation induces antinociception, recovers structural aspects and regulates mitochondrial homeostasis in peripheral nerve of diabetic mice. *Journal of biophotonics*. 2018;11(9):e201800110.
 17. M A, Ummer V S, Maiya AG, Hande M. Low level laser therapy for the patients with painful diabetic peripheral neuropathy - A systematic review. *Diabetes Metab Syndr*. 2019 Jul-Aug;13(4):2667-2670.
 18. Robinson CC, Klahr PDS, Stein C, Falavigna M, Sbruzzi G, Plentz RDM. Effects of monochromatic infrared phototherapy in patients with diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Braz J Phys Ther*. 2017 Jul-Aug;21(4):233-243.
 19. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, Kumar V, De Taboada L, Dey AB. Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial. *BMC Geriatr*. 2019 Aug 12;19(1):218.
 20. da Silva Leal MV, Lima MO, Nicolau RA, de Carvallho TMT, Abreu JAC, Pessoa DR, Arisawa EALS. Effect of Modified Laser Transcutaneous Irradiation on Pain and Quality of Life in Patients with Diabetic Neuropathy. *Photobiomodul Photomed Laser Surg*. 2020 Mar;38(3):138-144.
 21. Shanb AA, Youssef EF, Al Baker WI, Al-Khamis FA, Hassan A, Jatou NA. The Efficacy of Adding Electromagnetic Therapy or Laser Therapy to Medications in Patients With Diabetic Peripheral Neuropathy. *J Lasers Med Sci*. 2020

- 1
2
3 Winter;11(1):20-28.
- 4
5 22. Meyer-Hamme G, Friedemann T, Greten J, Gerloff C, Schroeder S.
6 Electrophysiologically verified effects of acupuncture on diabetic peripheral
7 neuropathy in type 2 diabetes: The randomized, partially double-blinded, controlled
8 ACUDIN trial. *J Diabetes*. 2021 Jun;13(6):469-481.
- 9
10 23. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus
11 photobiomodulation therapy. *Photomed Laser Surg*. 2015 Apr;33(4):183-4.
- 12
13 24. Merckies IS, Lauria G. 131st ENMC international workshop: selection of outcome
14 measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden,
15 The Netherlands. *Neuromuscul Disord*. 2006 Feb;16(2):149-56.
- 16
17 25. Brill V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic
18 polyneuropathy. *Diabetes Care*. 2002 Nov;25(11):2048-52.
- 19
20 26. Chen W, Zhang Y, Li X, Yang G, Liu JP. Chinese herbal medicine for diabetic
21 peripheral neuropathy. *Cochrane Database Syst Rev*. 2013 Oct 6;(10):CD007796.
- 22
23 27. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7:
24 Considering bias and conflicts of interest among the included studies. In: Higgins
25 JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
26 *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated*
27 *February 2021)*. Cochrane, 2021. Available
28 from www.training.cochrane.org/handbook.
- 29
30 28. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk
31 of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
32 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
33 *Interventions version 6.2 (updated February 2021)*. Cochrane, 2021. Available from
34 www.training.cochrane.org/handbook.
- 35
36 29. Higgins JPT, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized
37 trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
38 VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version*
39 *6.2 (updated February 2021)*. Cochrane, 2021. Cochrane, 2021. Available from
40 www.training.cochrane.org/handbook.
- 41
42 30. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-
43 analyses involving cross-over trials: methodological issues. *Int J Epidemiol*. 2002
44 Feb;31(1):140-9.
- 45
46 31. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH.
47 Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the
48 evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
49 Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions*
50 *version 6.2 (updated February 2021)*. Cochrane, 2021. Available from
51 www.training.cochrane.org/handbook.
- 52
53 32. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and
54 undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
55 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
56 *Interventions version 6.2 (updated February 2021)*. Cochrane, 2021. Cochrane,
57 2021. Available from www.training.cochrane.org/handbook.
- 58
59
60

Appendix 1. PubMed Search strategy

No	Item
#1	randomized controlled trial [pt]
#2	controlled clinical trial [pt]
#3	randomized [tiab]
#4	placebo [tiab]
#5	clinical trials as topic [mesh: noexp]
#6	randomly [tiab]
#7	trial [ti]
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	animals [mh] NOT humans [mh]
#10	#8 NOT #9
#11	diabetes mellitus [mh]
#12	diabet [tiab]
#13	#11 OR #12
#14	peripheral nervous system diseases[mh]
#15	#14 OR (neuropath OR polyneuropath)[tiab]
#16	#13 AND #15
#17	Diabetic Neuropathies[mh]
#18	#16 OR #17
#19	Low-Level Light Therapy [mh] OR photobiomodulation [mh]
#20	(Light Therapies, Low-Level OR Light Therapy, Low-Level OR Low Level Light Therapy OR Low-Level Light Therapies OR Therapies, Low-Level Light OR Therapy, Low-Level Light OR Photobiomodulation Therapy OR Photobiomodulation Therapies OR Therapies, Photobiomodulation OR Therapy, Photobiomodulation OR LLLT OR Laser Therapy, Low-Level OR Laser Therapies, Low-Level OR Laser Therapy, Low Level OR Low-Level Laser Therapies OR Laser Irradiation, Low-Power OR Irradiation, Low-Power Laser OR Laser Irradiation, Low Power OR Low-Power Laser Therapy OR Low Power Laser Therapy OR Laser Therapy, Low-Power OR Laser Therapies, Low-Power OR Laser Therapy, Low Power OR Low-Power Laser Therapies OR Low-Level Laser Therapy OR Low Level Laser Therapy OR Low-Power Laser Irradiation OR Low Power Laser Irradiation OR Laser Biostimulation OR Biostimulation, Laser OR Laser Phototherapy OR Phototherapy, Laser) [tiab]
#21	#19 OR #20
#22	#10 AND #18 AND #21

1
2
3 [pt] denotes a publication type term;
4 [ti] denotes a word in the title;
5
6 [mh] denotes a Medical Subject Heading (MeSH) term ('exploded');
7 [mesh: noexp] denotes a Medical Subject Heading (MeSH) term ('exploded')
8 [tiab] denotes a word in the title or abstract.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	8
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not amendments
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	8
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	8
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	3
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	11

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	5
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	4
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	5
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	3
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	5
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	6
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	6
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	6
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	6
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	6
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	7

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Low Level Light Therapy/Photobiomodulation for Diabetic Peripheral Neuropathy: Protocol of a Systematic Review and Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059476.R2
Article Type:	Protocol
Date Submitted by the Author:	17-Aug-2022
Complete List of Authors:	Wang, Jiayou; Shanghai University of Traditional Chinese Medicine Zouqin, Huang; Shanghai Pudong Hospital of Traditional Chinese Medicine Deng, Haiping; Shanghai University of Traditional Chinese Medicine Zhao, Ling; Shanghai University of Traditional Chinese Medicine Hongyong, Deng; Shanghai University of Traditional Chinese Medicine Liu, Jianping; Beijing University of Chinese Medicine, Centre for Evidence Based Chinese Medicine Shen, Xueyong; Shanghai University of Traditional Chinese Medicine, School of Acupuncture-moxibustion and Tuina; Shanghai Research Center of Acupuncture & Meridian Cheng, Ke; Shanghai University of Traditional Chinese Medicine, School of Acupuncture-moxibustion and Tuina; Shanghai Research Center of Acupuncture & Meridian
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Neurology
Keywords:	Laser therapy < DERMATOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, Neurological pain < NEUROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 Low Level Light Therapy/Photobiomodulation for Diabetic
5
6 Peripheral Neuropathy: Protocol of a Systematic Review and
7
8
9 Meta-analysis
10
11
12
13

14 Mr. Jia-You Wang, School of Acupuncture-moxibustion and Tuina, Shanghai University
15 of Traditional Chinese Medicine. 18702590670@163.com

16 Dr. Zou-Qin Huang, Shanghai Pudong Hospital of Traditional Chinese Medicine,
17 Shanghai, China. hzqmusic@yeah.net

18 Dr. Hai-Ping Deng, School of Acupuncture-moxibustion and Tuina, Shanghai University
19 of Traditional Chinese Medicine. hpdeng307@126.com

20 Dr. Ling Zhao, School of Acupuncture-moxibustion and Tuina, Shanghai University of
21 Traditional Chinese Medicine. zhao3helen@sina.com

22 Dr. Hong-Yong Deng, Collaborative Innovation Center, Shanghai University of Traditional
23 Chinese Medicine. dephew@126.com

24 Dr. Jian-Ping Liu, Centre for Evidence Based Chinese Medicine, Beijing University of
25 Chinese Medicine, Beijing, 100029, China, liujp@bucm.edu.cn

26 Dr. Xue-Yong Shen, School of Acupuncture-moxibustion and Tuina, Shanghai University
27 of Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian.
28 snowysh@hotmail.com

29 Dr. Ke Cheng, School of Acupuncture-moxibustion and Tuina, Shanghai University of
30 Traditional Chinese Medicine, Shanghai Research Center of Acupuncture & Meridian.
31 cheng_ker@hotmail.com

32 Corresponding authors: Ke Cheng, Xue-Yong Shen

33 Jia-You Wang and Zou-Qin Huang contributed equally to this article.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes that strongly impact the patients' quality of life and working ability. Evidence indicated that low level light therapy (LLLT)/photobiomodulation might be effective for neuropathy. However, the effect of LLLT for DPN is not clear. The objective of this systematic review and meta-analysis is to determine the effects and safety of LLLT/photobiomodulation for DPN, in comparison with other methods such as sham light, no treatment, other active treatment, and LLLT as an additional treatment compared with another treatment alone.

Methods and analysis: We will search eight databases from their inception to the date before the review submission. Randomized controlled trials (RCTs) will be included. Two reviewers will independently extract data using a structured data extraction method and assess the risk of bias in the included studies. Data will be synthesized using standardized mean difference (SMD) or risk ratio (RR) with 95% confidence intervals (CI) for continuous and dichotomous data, respectively. The primary outcome will be change in pain and secondary outcomes will include global symptom improvement, functional impairment and disability, impairment of sensation, quality of life, nerve conduction, as well as adverse events. Sensitivity and subgroup analysis will be employed to explore the influence of possible clinical and methodological characteristics. Publication bias will be assessed using funnel plot. We will conduct meta-analysis with RevMan 5.4 and evaluate quality of the evidence using GRADE approach.

Ethics and dissemination: This study does not require ethics approval. Our findings will be disseminated in the peer-reviewed publications.

Systematic review registration: submitted in PROSPERO ID: CRD42021276056

Keywords: low level light therapy, photobiomodulation, diabetic peripheral neuropathy, pain, systematic review

Strengths and limitations of this study

- The systematic review method in the protocol follows standard methodological procedures recommended in the Cochrane Handbook in terms of literature searching and screening, data collecting, risk of bias assessing and data synthesis.
- The reporting of the protocol follows the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols guidelines.
- This study will search eight databases and two trial registries without language restrictions.
- The main expected limitations are variations in light treatments and in outcome measures that may introduce heterogeneity or imprecision, which will influence the reliability of the evidence.

INTRODUCTION

Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes and affects nearly 50% of adults with diabetes during their lifetime.^[1] DPN strongly impacts the patients' quality of life and capacity for work. It leads to foot ulcer in 50% diabetes, and even cause lower limb amputation.^[1] People with type 2 diabetes suffered higher risk of DPN than type 1.^[1] DPN is recognized by damage to peripheral nerves, commonly occurring in the lower limbs and occasionally affecting the hands. However, up to 50% of patients never experience symptoms, thus diagnosis can only be made in accidental examination or until foot ulcers appear. For patients who have already experienced symptoms, numbness, dryness, burning pain, needle-like pain and some other abnormal sensations are most frequently mentioned. ^[2]

Significant risk factors for DPN include diabetes duration, age and glycosylated hemoglobin.^[3,4] Some other factors, including hypertension, hyperlipidaemia and obesity may also play a role at varying degrees. ^[5]

Other than improving glycemic control, there is no specific treatment for the underlying nerve damage. Enhanced glucose control can effectively prevent DPN in type 1 diabetes, whereas the evidence for the effect of glycemic control is not strong in type 2 diabetes.^[6] Furthermore, enhanced glucose control can increase the risk of severe hypoglycemic episodes.^[6] Some symptomatic therapies, such as pregabalin, duloxetine or gabapentin are recommended as first-line pharmacological treatment for relieving painful symptoms. Tricyclic antidepressants, venlafaxine, carbamazepine, opioids and topical capsaicin are also probably effective in relieving pain. ^[7,8] However, these drugs are accompanied with a variety of adverse events, such as dry mouth, sedation, dizziness, confusion, orthostatic hypotension, headache, nausea, constipation, diarrhea, etc.^[9]

Non-pharmacological therapy, such as low level light therapy (LLLT), has also been used to treat DPN due to its function in alleviating pain^[10] and improving lower limbs sensation^[11,12]. LLLT, also known as photobiomodulation, has been in use from its invention in 1960s. The light used in LLLT is mainly in the red (wavelength of 600-700 nm) and near-infrared (NIR, wavelength of 780-1100 nm) region. ^[13,14] The red and NIR light is mostly absorbed by the mitochondrial enzyme (i.e., cytochrome-c-oxidase), the key chromophore in the cellular response to LLLT, to increase adenosine triphosphate (ATP) production, modulation of reactive oxygen species (ROS), and the induction of transcription factors. ^[13,14,15] The mid-IR (infrared) including carbon dioxide laser at wavelength of 10.6 μm and broad band IR source in the 10-50 μm range are also reported as effective LLLT light. Mid-IR light is considered to be absorbed by water in some nanostructured form possibly present in biological membranes.^[13] On the tissue level, LLLT has been used to inhibit pain and pathological conditions associated with the nervous system. It exerts potent anti-inflammatory effects in the peripheral nervous system and promotes functional recovery and regeneration of peripheral nerves after

1
2
3 injury, also in DPN. [14,16] The effect of LLLT depends on the type of light, irradiation
4 mode, power density and the properties of irradiated tissue.[13]

5
6 Although two systematic reviews [17, 18] have evaluated the effects of
7 LLLT/photobiomodulation for DPN, they both included only a small number of studies in
8 published in English language. Furthermore, one [17] of them only provided qualitative
9 description of the included studies. With some new and larger-sample size RCTs [19-
10 22] published, it is important to conduct an updated systematic review and meta-analysis
11 of LLLT for DPN.
12
13

14 15 16 **OBJECTIVE**

17
18
19 The objective of this review is to determine the benefit and harm of
20 LLLT/photobiomodulation in comparison to sham light, no treatment, other active
21 treatment, or as an additional treatment compared with another treatment alone in
22 patients with DPN. The benefit will include its effect in relieving pain and global
23 symptoms, as well as improving nerve function as well as quality of life.
24
25

26 27 **METHODS AND ANALYSIS**

28
29
30 We will use standard methodological procedures following the Cochrane Handbook. The
31 planned start date of the study is July 2021 and end dates is December 2022.
32
33

34 **Eligibility criteria for included studies**

35 36 37 Types of studies

38
39 We will include randomized controlled trials assessing the benefits and harms of
40 LLLT/photobiomodulation for DPN. Trials with randomization of interventions taking place
41 within individuals to different body parts (e.g., to the two legs) will also be included.
42
43

44 45 46 Types of population

47
48 We will include participants of any age and sex, with either form of diabetes, that were
49 diagnosed as DPN. Although many light therapies are focused on DPN with type 2
50 diabetes, there are also studies involving patients with type 1 diabetes. We believe the
51 mechanisms of DPN from both types of diabetes are similar. Thus, we include patients
52 with either form of diabetes.
53

54 55 56 Types of intervention

57
58 LLLT/photobiomodulation utilizes non-ionizing forms of light sources, including lasers,
59 LEDs, and broadband light, in the visible and infrared spectrum.[23] The commonly used
60 lights in DPN may include red (wavelength of 780-1100 nm), NIR (wavelength of 780-

1
2
3 1100 nm), mid-IR (e.g., 10.6µm) and broad band IR light in the 10-50 µm.[13] We will
4 compare true LLLT versus sham LLLT, LLLT versus no specific treatment, LLLT versus
5 other specific treatment, or LLLT plus another treatment (usually conventional treatment)
6 versus another treatment only. In order to eliminate confounding effects, we will only
7 include RCTs that used the same co-intervention in each group.
8
9

10 Types of outcome measures

11 **Main outcome**

12
13
14
15
16 The main outcome will be change in pain measured using a validated scale including
17 visual analogue scale (VAS), numeric rating scale (NRS), Likert scale, or verbal
18 description scale (VDS), etc.
19

20 **Additional outcomes**

- 21
22
23 1. Global symptom improvement measured by a validated instrument such as neuropathy
24 symptom score (NSS), neuropathy total symptom score (NTSS), or total neuropathy
25 score (TNS). [24-26], The DPN examination scales such as Michigan neuropathy screening
26 instrument (MNSI), Michigan diabetic neuropathy score (MDNS) and Toronto clinical
27 scoring system (TCSS) will not be considered as validated instruments in evaluating DPN
28 symptoms. Where this continuous outcome was not available, the primary outcome will be
29 an improvement of 30% or more in a validated clinical global symptom score.[27]
30
31
32
33 2. Change in functional impairment and disability by neuropathy impairment score (NIS)
34 or neuropathy defects score (NDS) in the lower limbs.
35
36
37 3. Change in impairment of sensation in quantitative sensory testing (e.g., vibration
38 perception threshold, thermal threshold and Semmes-Weinstein Monofilaments (SWM)).
39
40
41
42 4. Change in quality of life by SF-36 or NeurQoL, etc.
43
44
45 5. Change in nerve conduction function measured by motor or sensory nerve conduction
46 velocity (NCV), sensory nerve action potential (SNAP) or compound muscle action
47 potential (CMAP).
48
49
50 6. Number of participants experiencing adverse events.
51
52 7. Serious adverse events.
53

54 The time point of follow-up will be at equal or less than 3 months (closest to 2 months)
55 after randomization for short term and at more than 3 months (closest to 6 months) after
56 randomization for long term.
57

58 **Search methods for identification of studies**

1
2
3 We will search, with no time and language restrictions, the following databases for
4 relevant literature: PubMed (MEDLINE), Embase, the Cochrane Central Register of
5 Controlled Trials (CENTRAL) and Web of Science, as well as Chinese language
6 databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP
7 Chinese Science and Technology Journal Database (VIP) and SinoMed. Furthermore,
8 the search will also include the two trial registries ClinicalTrials.gov and the World Health
9 Organization International Clinical Trials Registry
10 Platform (<https://trialssearch.who.int/>). The electronic database search will be
11 supplemented by a manual search of the reference lists of included articles. The search
12 strategy is illustrated in Appendix 1. The last search date will be the date before the
13 submission of the full review. The studies in Chinese language will be translated by JYW
14 and checked by KC.

20 **Study selection**

21
22 At least one author (JYW or ZQH) will screen the title and abstract of all records identified
23 by searching. We will obtain the full text of potentially relevant reports and two authors
24 (JYW and ZQH) will independently review the full text to assess its eligibility. We will
25 resolve disagreements by discussion. In case of disagreement, a third author (KC) will
26 make the final decision on the study selection.

30 **Data extraction and management**

31
32 Two review authors (JYW and ZQH) will independently extract data concerning details of
33 study population, intervention, and outcomes using a structured data extraction form and
34 enter it into a Microsoft excel spreadsheet following section 7.7 of Cochrane
35 Handbook.^[28] We will consult the other review author (KC) if there is any conflict.

36
37 If the publication did not report outcome data or the data was reported ambiguously, we
38 will request the corresponding authors of the study to provide additional information or
39 clarification by email.

44 **Assessment of treatment adequacy**

45
46 Two experts, who have a clinical or research experience of more than 5 years in
47 LLLT/photobiomodulation therapy or in DPN treatment, and who have previously worked
48 on RCTs or systematic reviews, will independently assess the adequacy of the light
49 therapy and the control therapy in the trials. Five aspects of the light treatment will be
50 assessed for adequacy: 1) selection of light (including wavelength, power density and
51 energy density) 2) choice of irradiation location; 3) total number of sessions; 4) treatment
52 duration; 5) treatment frequency. The validity of the sham intervention will also be
53 assessed using an open-ended question. The experts will be provided with only the part
54 of each publication that describes the light and control procedures, so that their
55 assessments cannot be influenced by the results of the trials. Discrepancies between the
56
57
58
59
60

1
2
3 two experts will achieve consensus by discussion.
4

5 **Assessment of risk of bias**

6
7
8 Two review authors (JYW and ZQH) independently will assess the risk of bias in the
9 studies that were included in this review according to the criteria described in the section
10 8.2.3 of Cochrane Handbook for Systematic Reviews of Interventions. [29] We will resolve
11 conflicts by consulting the other review author (KC).
12

13
14 The items involve the following domains: sequence generation, allocation concealment,
15 blinding of participants, personnel and outcome assessors, incomplete outcome data,
16 selective outcome reporting, and other sources of bias.
17

18 **Measures of treatment effect**

19
20
21 Mean difference or standards mean difference with 95% CI will be used for continuous
22 outcome and relative ratios (RR) with 95% CI will be used for dichotomous data. Data
23 of studies that are sufficiently similar in terms of their comparisons and outcome
24 measurements will be pooled. The data will be pooled by using random-effects model
25 when studies are heterogeneous on clinical and methodological characteristics, and by
26 using fixed-effect model when they are homogeneous. We will report the data separately
27 if the study cannot be combined. We will use mean difference (MD) for single trial
28 comparisons and for RCTs that used the same instrument to measure the same
29 outcome. For the RCTs that assessed the same outcome by various instruments, we will
30 use standard mean difference (SMD). Analyses will be performed by intention to treat,
31 where possible.
32
33
34
35
36

37 **Unit of analysis issues**

38
39
40 We will also include data from trials with different interventions being applied to different
41 body parts, if the information is available. The analysis will be account for the pairing of
42 parts within individuals in the same way that pairing of intervention periods in the
43 crossover trial.[30] Continuous data from this kind of trial will be analyzed using one of the
44 two approaches: use the results from paired analyses if reported in the original article;
45 treat the study as a parallel trial and pool the interventional parts and compare these to
46 the pooled control parts. Dichotomous outcomes for this kind of trial require more
47 complicated analysis methods and we will consult with a statistician. [31]
48
49
50

51 **Dealing with missing data**

52
53
54 For the missing data, we will contact the original author. If we fail to obtain the missing
55 data, we will discuss the potential impact of the dropout for the conclusion of the review.
56

57 **Assessment of heterogeneity**

1
2
3 We will use I^2 statistic to assess statistical heterogeneity. If the I^2 value is greater than
4 50%, we will conduct subgroups to explore the sources of heterogeneity.
5
6

7 **Reporting bias**

8
9 We will make a funnel plot to assess publication bias if the number of studies is more
10 than 10.
11
12

13 **Sensitivity analysis**

14
15 We will perform sensitivity analysis excluding the trials with high risk of bias when data
16 are adequate. For pooled analyses with continuous data, we will consider analyses
17 based on change scores to be the primary analysis, and analyses based on post-
18 treatment scores to be sensitivity analysis.
19
20
21

22 **Subgroup analysis**

23
24 If we find sufficient number of RCTs, we will perform subgroup analyses according to:

- 25 1. Type of diabetes (type 1 or type 2 diabetes mellitus)
- 26 2. Type of light (red, infrared, or other)
- 27 3. Dosage of light treatment: including power density, energy density, as well as duration
28 and frequency of the treatment according to the assessment results of treatment
29 adequacy by the experts.
30
31
32
33
34
35

36 **Confidence in cumulative evidence**

37
38 We will use GRADE system to assess the confidence of our evidence considering five
39 criteria: study limitations, consistency of effect, imprecision, indirectness, and publication
40 bias. We will conduct the assessment in accordance with section 14.2 of the Cochrane
41 Handbook [32] using GRADEpro software.
42
43
44
45

46 **Patient and public involvement**

47
48 No patient involved
49
50

51 **DISCUSSION**

52
53 Evidences for LLLT/photobiomodulation in treating diabetic peripheral neuropathy are
54 deficient so far. A 2017 systematic review focused on using infrared light for
55 DPN.^[18] A more recent systematic review from 2019 studied LLLT for painful diabetic
56 neuropathy.^[17] Both reviews included only six studies each. Among the six studies
57
58
59
60

1
2
3 included the 2019 review, three were non-RCTs, thus the 2019 review only narratively
4 described the results of the individual study without conducting any meta-analysis or
5 assessing the risk of bias of the included studies. In addition, the conclusions of the two
6 reviews were inconsistent with each other. The 2017 review showed limited evidence of
7 infrared phototherapy resulting in short-term improvement of tactile sensitivity, but not in
8 neuropathic pain relief. In contrast, the 2019 review concluded LLLT is associated with a
9 positive effect in relieving neuropathic pain.
10
11
12

13 Compared to previous reviews, we will update the search to date to include more recent
14 studies and will expand our search scope to Chinese language databases to collect more
15 evidences. Furthermore, we will include more types of lights, not focusing only on
16 infrared lights as in the 2017 review, since other than infrared light, visible lights are also
17 used in clinic for DPN. In terms of the outcomes, the 2017 review ^[18] investigated plantar
18 tactile sensitivity and pain; the 2019 review ^[17] focused on pain and nerve
19 conduction velocity. In additional to the aforementioned outcomes, we will also be
20 concerned about global symptom improvement, functional impairment and disability,
21 quality of life, as well as adverse events due to the therapy. Compared with the
22 2017 review ^[18] which performed subgroup analysis according to the type of comparison
23 and length of follow-up, we will carry out subgroup analysis focusing more on the
24 differences in the populations and intervention characteristics (e.g., type of diabetes, type
25 of light and dosage of therapy) according to the suggestion in the Cochrane
26 Handbook.^[33]
27
28
29
30
31
32

33 There are some expected limitations in this review. First, the heterogeneity in light
34 treatment including different types of light, irradiation modes, power densities and sites of
35 irradiation, may result in important heterogeneity in pooled results. Second, the global
36 symptom outcome is usually assessed with composite measures and the measures vary
37 among studies. This may introduce heterogeneity and render pooled estimates difficult to
38 explain. Last, the variations in electrophysiologic measures and quantitative sensory
39 testing among studies may result in only a limited number of studies that can be pooled
40 for a certain outcome. This may influence the reliability of the evidence.
41
42
43

44 **List of abbreviations**

45
46 CMAP: compound muscle action potential; DPN; diabetic peripheral neuropathy; LLLT:
47 low level light therapy; GRADE: grading of recommendations, assessment, development
48 and evaluations; MDNS: Michigan diabetic neuropathy score; MNSI: Michigan
49 neuropathy screening instrument; NCV: nerve conduction velocity; NDS: neuropathy
50 defects score; NeuQoL: quality of life in neurological disorders; NIR: near- infrared; NIS:
51 neuropathy impairment score; NRS: numeric rating scale; RCT: randomized controlled
52 trial; SF-36: 36-item short-form health survey ; SNAP: sensory nerve action potential;
53 TCSS: Toronto clinical scoring system; VAS: visual analogue scale; VDS: Likert scale, or
54 verbal description scale.
55
56
57
58
59
60

DECLARE

Ethics and dissemination

This study does not require ethics approval. Our findings will be disseminated in peer-reviewed publications.

Contributors

JYW: data acquisition and original draft writing; ZQH: clinical guidance, data acquisition and original draft writing; HPD: clinical guidance and draft revision; LZ: clinical guidance and draft revision; HYD: methodology support and draft revision; JPL: methodology support and revision of protocol and manuscript; XYS: topic conception, clinical guidance and revision of manuscript; KC: topic conception, protocol design, original draft writing and revision of manuscript.

Funding

This work is supported by funding from the National Key R&D Program of China (grand number 2019YFC1709803) and National Natural Science Foundation of China (grand number 81873183). Jian-Ping Liu was partially supported by the NCCIH grant (AT001293 with sub-award No. 020468C). The funder had no role in study design, data collection and analysis, interpretation of result, or writing the manuscript.

Availability of data and materials

The datasets generated and/or analyzed during the current study will be available from the corresponding author according to the institution guideline on materials and data transfer agreements.

Competing interests

Xueyong Shen and Ke Cheng have had a patent issued for a type of laser therapy apparatus simulating the infrared radiation spectrum of traditional Chinese moxibustion (China Invention Patent ZL 200910056991.4; issued December 1, 2010).

Patient and Public Involvement statement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication: Not applicable.

REFERENCE

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
1. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep*. 2019 Aug 27;19(10):86.
 2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care*. 2005 Apr;28(4):956-62.
 3. Liu X, Xu Y, An M, Zeng Q. The risk factors for diabetic peripheral neuropathy: A meta-analysis. *PLoS One*. 2019 Feb 20;14(2):e0212574.
 4. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. *Rev Diabet Stud*. 2015 Spring-Summer;12(1-2):48-62.
 5. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. *Int J Clin Pract*. 2006 Nov;60(11):1471-83.
 6. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev*. 2012 Jun 13;6(6):CD007543.
 7. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology*. 2011 May 17;76(20):1758-65.
 8. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021 Jan;44(Suppl 1):S151-S167.
 9. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. *Am J Health Syst Pharm*. 2004 Jan 15;61(2):160-73; quiz 175-6.
 10. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, et al. Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial. *BMC geriatrics*. 2019;19(1):218.
 11. Harkless LB, DeLellis S, Carnegie DH, Burke TJ. Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy--MIRE. *J Diabetes Complications*. 2006 Mar-Apr;20(2):81-7.
 12. DeLellis SL, Carnegie DH, Burke TJ. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. *J Am Podiatr Med Assoc*. 2005 Mar-Apr;95(2):143-7.
 13. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. *Ann Biomed Eng*. 2012 Feb;40(2):516-33.
 14. de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. *IEEE J Sel Top Quantum Electron*. 2016 May-Jun;22(3):7000417.
 15. Wang X, Tian F, Soni SS, Gonzalez-Lima F, Liu H. Interplay between up-regulation

- of cytochrome-c-oxidase and hemoglobin oxygenation induced by near-infrared laser. *Sci Rep*. 2016 Aug 3;6:30540.
16. da Silva Oliveira VR, Cury DP, Yamashita LB, Esteca MV, Watanabe IS, Bergmann YF, et al. Photobiomodulation induces antinociception, recovers structural aspects and regulates mitochondrial homeostasis in peripheral nerve of diabetic mice. *Journal of biophotonics*. 2018;11(9):e201800110.
 17. M A, Ummer V S, Maiya AG, Hande M. Low level laser therapy for the patients with painful diabetic peripheral neuropathy - A systematic review. *Diabetes Metab Syndr*. 2019 Jul-Aug;13(4):2667-2670.
 18. Robinson CC, Klahr PDS, Stein C, Falavigna M, Sbruzzi G, Plentz RDM. Effects of monochromatic infrared phototherapy in patients with diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Braz J Phys Ther*. 2017 Jul-Aug;21(4):233-243.
 19. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, Kumar V, De Taboada L, Dey AB. Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial. *BMC Geriatr*. 2019 Aug 12;19(1):218.
 20. da Silva Leal MV, Lima MO, Nicolau RA, de Carvalho TMT, Abreu JAC, Pessoa DR, Arisawa EALS. Effect of Modified Laser Transcutaneous Irradiation on Pain and Quality of Life in Patients with Diabetic Neuropathy. *Photobiomodul Photomed Laser Surg*. 2020 Mar;38(3):138-144.
 21. Shanb AA, Youssef EF, Al Baker WI, Al-Khamis FA, Hassan A, Jatou NA. The Efficacy of Adding Electromagnetic Therapy or Laser Therapy to Medications in Patients With Diabetic Peripheral Neuropathy. *J Lasers Med Sci*. 2020 Winter;11(1):20-28.
 22. Meyer-Hamme G, Friedemann T, Greten J, Gerloff C, Schroeder S. Electrophysiologically verified effects of acupuncture on diabetic peripheral neuropathy in type 2 diabetes: The randomized, partially double-blinded, controlled ACUDIN trial. *J Diabetes*. 2021 Jun;13(6):469-481.
 23. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. *Photomed Laser Surg*. 2015 Apr;33(4):183-4.
 24. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total
 25. Bastyr EJ, 3rd, Price KL, Bril V. Development and validity testing of the neuropathy total symptom 25. score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. *Clinical therapeutics*. 2005;27(8):1278-94
 26. Merkies IS, Lauria G. 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. *Neuromuscul Disord*. 2006 Feb;16(2):149-56.
 27. Chen W, Zhang Y, Li X, Yang G, Liu JP. Chinese herbal medicine for diabetic peripheral neuropathy. *Cochrane Database Syst Rev*. 2013 Oct 6;(10):CD007796.
 28. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated*

- 1
2
3 February 2021). Cochrane, 2021. Available
4 from www.training.cochrane.org/handbook.
5
6 29. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk
7 of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
8 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
9 *Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Available from
10 www.training.cochrane.org/handbook.
11
12 30. Higgins JPT, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized
13 trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
14 VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version
15 6.2 (updated February 2021). 31. Cochrane, 2021. Cochrane, 2021. Available from
16 www.training.cochrane.org/handbook.
17
18 31. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-
19 analyses involving cross-over trials: methodological issues. *Int J Epidemiol.* 2002
20 Feb;31(1):140-9.
21
22 32. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH.
23 Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the
24 evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
25 Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions*
26 version 6.2 (updated February 2021). Cochrane, 2021. Available from
27 www.training.cochrane.org/handbook.
28
29 33. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and
30 undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
31 T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of*
32 *Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Cochrane,
33 2021. Available from www.training.cochrane.org/handbook.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PubMed search strategy

No	Item
#1	randomized controlled trial [pt]
#2	controlled clinical trial [pt]
#3	randomized [tiab]
#4	placebo [tiab]
#5	clinical trials as topic [mesh: noexp]
#6	randomly [tiab]
#7	trial [ti]
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	animals [mh] NOT humans [mh]
#10	#8 NOT #9
#11	diabetes mellitus [mh]
#12	Diabet* [tiab]
#13	#11 OR #12
#14	peripheral nervous system diseases[mh]
#15	#14 OR (neuropath* OR nervous)[tiab]
#16	#13 AND #15
#17	Low-level light therapy [mh]
#18	(Light Therapies OR Light Therapy OR Low Level Light Therapy OR
#19	Low-Level Light Therapies OR Laser Therapy, Low-Level OR Low-Level Laser Therapies OR Laser Irradiation, Low-Power OR Irradiation, Low-Power Laser OR Low-Power Laser Therapy OR Low Power Laser Therapy OR Laser Therapy, Low-Power OR Laser Therapies, Low-Power OR Laser Therapy, Low Power OR Low-Power Laser OR LLLT OR biostimulation OR phototherapy OR photobiomodulation OR infrared OR photon stimulation) [tiab]
	#10 AND #16 AND #17

[pt] denotes a publication type term;

[ti] denotes a word in the title;

[mh] denotes a Medical Subject Heading (MeSH) term ('exploded');

[mesh: noexp] denotes a Medical Subject Heading (MeSH) term ('exploded')

[tiab] denotes a word in the title or abstract.

Embase search strategy

- #1 'randomized controlled trial'/exp
- #2 'randomization'/exp
- #3 'double blind procedure'/exp
- #4 'single blind procedure'/exp
- #5 random*:ab,ti
- #6 #1 OR #2 OR #3 OR #4 OR #5
- #7 'animal'/exp OR 'animal experiment'/exp
- #8 'human'/exp

1
 2
 3 #9 #7 AND #8
 4 #10 #7 NOT #9
 5 #11 #6 NOT #10
 6 #12 'clinical trial'/exp
 7 #13 (clin* NEAR/3 trial*):ab,ti
 8 #14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti
 9 #15 'placebo'/exp
 10 #16 placebo*:ab,ti
 11 #17 random*:ab,ti
 12 #18 'experimental design'/exp
 13 #19 'crossover procedure'/exp
 14 #20 'control group'/exp
 15 #21 'latin square design'/exp
 16 #22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
 17 #23 #22 NOT #10
 18 #24 #23 NOT #11
 19 #25 'comparative study'/exp
 20 #26 'evaluation'/exp
 21 #27 'prospective study'/exp
 22 #28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti
 23 #29 #25 OR #26 OR #27 OR #28
 24 #30 #29 NOT #10
 25 #31 #30 NOT (#11 OR #23)
 26 #32 #11 OR #24 OR #31
 27 #33 'diabetes mellitus'/exp
 28 #34 Diabet*:ab,ti
 29 #35 #33 OR #34
 30 #36 'peripheral nervous system diseases'/exp
 31 #37 neuropath*:ab,ti OR nervous:ab,ti
 32 #38 #36 OR #37
 33 #39 #35 AND #38
 34 #40 'Low-Level Light Therapy'/exp
 35 #41 (Light Therapies OR Light Therapy OR Low Level Light Therapy OR Low-Level
 36 Light Therapies OR Laser Therapy, Low-Level OR Low-Level Laser Therapies OR
 37 Laser Irradiation, Low-Power OR Irradiation, Low-Power Laser OR Low-Power Laser
 38 Therapy OR Low Power Laser Therapy OR Laser Therapy, Low-Power OR Laser
 39 Therapies, Low-Power OR Laser Therapy, Low Power OR Low-Power Laser OR
 40 LLLT OR biostimulation OR phototherapy OR photobiomodulation OR infrared OR
 41 photon stimulation)*:ab,ti
 42 #42 #40 OR #41
 43 #43 #32 AND #39 AND #42

CENTRAL search strategy

#1MeSH descriptor diabetes mellitus explode all trees

1
2
3 #2(diabet*)
4 #3 (#1 or #2)
5 #4MeSH descriptor Peripheral Nervous System Diseases explode all trees
6 #5(neuropath* or nervous)
7 #6(#4 or #5)
8 #7(#3 and #6)
9
10 #8 MeSH descriptor: [Low-Level Light Therapy] explode all trees
11 #9 (Light Therapies OR Light Therapy OR Low Level Light Therapy OR Low-Level
12 Light Therapies OR Laser Therapy, Low-Level OR Low-Level Laser Therapies OR
13 Laser Irradiation, Low-Power OR Irradiation, Low-Power Laser OR Low-Power Laser
14 Therapy OR Low Power Laser Therapy OR Laser Therapy, Low-Power OR Laser
15 Therapies, Low-Power OR Laser Therapy, Low Power OR Low-Power Laser OR
16 LLLT OR biostimulation OR phototherapy OR photobiomodulation OR infrared OR
17 photon stimulation)
18 #10 #8 and #9
19 #11 #7 and #10
20
21
22
23
24

Web of Science search strategy

25
26 #1 TS=(diabetes mellitus) OR TS=(diabet*)
27 #2 TS=(neuropath*) OR TS=(nervous)
28 #3 #2 AND #1
29 #4 TS=(Light Therapies OR Light Therapy OR Low Level Light Therapy OR
30 Low-Level Light Therapies OR Laser Therapy, Low-Level OR Low-Level Laser
31 Therapies OR Laser Irradiation, Low-Power OR Irradiation, Low-Power Laser OR
32 Low-Power Laser Therapy OR Low Power Laser Therapy OR Laser Therapy,
33 Low-Power OR Laser Therapies, Low-Power OR Laser Therapy, Low Power OR
34 Low-Power Laser OR LLLT OR biostimulation OR phototherapy OR
35 photobiomodulation OR infrared OR photon stimulation)
36 #6 #4 AND #3
37
38
39
40
41

China National Knowledge Infrastructure (CNKI)

42
43 (((TKA='糖尿病') AND (TKA='周围神经病变'+ '神经病变')) OR TKA='DPN') AND
44 (TKA='激光'+ '光疗'+ '光调节'+ '低能量激光'+ '低强度激光'+ '红外'+ '红光'+ '红外线')
45 TKA means title, keyword and abstract
46
47
48

WanFang databases

49
50 主题:(激光 or 光疗 or 光调节 or 低能量激光 or 低强度激光 or 红外 or 红
51 光 or 红外线) and((主题:(糖尿病) and 主题:(周围神经病变 or 神经病变)) or 主
52 题:(DPN))
53
54

Chinese Scientific Journal Database (VIP)

55
56 M=(激光 OR 光疗 OR 光调节 OR 低能量激光 OR 低强度激光 OR 红外 OR
57 红光 OR 红外线) AND((M=(糖尿病) AND M=(周围神经病变 OR 神经病变)) OR
58 M=(DPN))
59
60

1
2
3 M means title or keyword
4
5

6 **SinoMed**

7 ("激光"[常用字段:智能] OR "光疗"[常用字段:智能] OR "光调节"[常用字段:智能]
8 OR "低能量激光"[常用字段:智能] OR "低强度激光"[常用字段:智能] OR "红外"[常
9 用字段:智能] OR "红光"[常用字段:智能] OR "红外线"[常用字段:智能]) AND(("糖
10 尿病"[常用字段:智能] AND("神经病变"[常用字段:智能] OR "周围神经病变"[常用
11 字段:智能])) OR ("DPN"[常用字段:智能]))
12
13
14
15

16 **US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov)**

17 (diabetic OR diabetes OR diabete) AND (Neuropathies OR Neuropathy) AND (Light
18 Therapies OR Photobiomodulation OR laser OR LLLT)
19
20

21 **World Health Organization International Clinical Trials Registry Platform**

22 (diabetic OR diabetes) AND (neuropath)AND (Light Therapies OR
23 Photobiomodulation OR OR laser OR LLLT)
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	8
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not amendments
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	8
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	8
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	3
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	11

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	5
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	4
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	5
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	3
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	5
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	6
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	6
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	6
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	6
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	6
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	7

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.